Skip to main content
. 2024 Nov 27;30:e945899. doi: 10.12659/MSM.945899

Table 3.

Comparison of glucose metabolism parameters between the SCORE2 and SCORE2-OP groups.

Parameter CVD risk based on SCORE-OP/SCORE-OP2 P value
Low and moderate risk (N=16) High risk (N=28) Very high risk (N=62)
Fasting glucose [mmol/L] 5.35 (5.08–5.61) 5.78 (5.39–6.03) 5.83 (5.22–6.28) 0.035a,b
Glucose after 120 min [mmol/L] (glucose tolerance test) 7.20 (6.33–7.92) 7.19 (5.87–8.75) 6.39 (5.61–7.92) 0.5449
Glucose after 60 min [mmol/L] (glucose tolerance test) 11.92 (9.25–12.28) 9.85 (9.61–12.21) 9.42 (7.83–11.22) 0.2054
Fasting insulin [pmol/L] 12.30 (7.20–13.40) 6.60 (4.60–35.80) 6.15 (4.30–9.65) 0.08
Insulin after 60 min [pmol/L] (glucose tolerance test) 139.40 (38.50–170.90) 53.85 (35.80–90.40) 55.05 (40.70–76.60) 0.1225
HbA1C [%] 5.59±0.33 5.74±0.28 5.92±0.67 0.29
HOMA-IR index 1.07 (1.01–3.40) 1.61 (1.07–2.46) 2.28 (1.4–3.04) 0.2735

HbA1C – glycated hemoglobin; HOMA-IR – homeostatic model assessment for insulin resistance. Kruskall-Wallis test with the post hoc multiple comparison test.

a

Kruskall-Wallis test: significant difference for: low risk vs high risk;

b

Kruskall-Wallis test: significant difference for: low risk vs moderate risk.